Abstract 5259: Urolithin A prevents pancreatic tumor growth and increases survival by inhibiting PI3K/PDK1 and STAT3 signaling

Author(s):  
Supriya Srinivasan ◽  
Venkatakrishna Jala ◽  
Kumar Honnenahally ◽  
Jason Castellanos ◽  
Praveen Kumar Vermula ◽  
...  
2016 ◽  
Vol 151 (1) ◽  
pp. 180-193.e12 ◽  
Author(s):  
Sonja M. Wörmann ◽  
Liang Song ◽  
Jiaoyu Ai ◽  
Kalliope N. Diakopoulos ◽  
Magdalena U. Kurkowski ◽  
...  

2010 ◽  
Vol 48 (08) ◽  
Author(s):  
N Azoitei ◽  
GV Pusapati ◽  
A Kleger ◽  
C Brunner ◽  
F Genze ◽  
...  

2012 ◽  
Vol 38 (12) ◽  
pp. 1121-1131
Author(s):  
Xiao-Hui WANG ◽  
Ya-Min ZHENG ◽  
Ye-Qing CUI ◽  
Shuang LIU ◽  
Hai-Chen SUN ◽  
...  

Author(s):  
Shasha Liu ◽  
Chaoqi Zhang ◽  
Boqiao Wang ◽  
Huanyu Zhang ◽  
Guohui Qin ◽  
...  

AbstractGlioma stem cells (GSCs) contribute to the malignant growth of glioma, but little is known about the interaction between GSCs and tumor microenvironment. Here, we found that intense infiltration of regulatory T cells (Tregs) facilitated the qualities of GSCs through TGF-β secretion that helped coordinately tumor growth. Mechanistic investigations indicated that TGF-β acted on cancer cells to induce the core cancer stem cell-related genes CD133, SOX2, NESTIN, MUSASHI1 and ALDH1A expression and spheres formation via NF-κB–IL6–STAT3 signaling pathway, resulting in the increased cancer stemness and tumorigenic potential. Furthermore, Tregs promoted glioma tumor growth, and this effect could be abrogated with blockade of IL6 receptor by tocilizumab which also demonstrated certain level of therapeutic efficacy in xenograft model. Additionally, expression levels of CD133, IL6 and TGF-β were found to serve as prognosis markers of glioma patients. Collectively, our findings reveal a new immune-associated mechanism underlying Tregs-induced GSCs. Moreover, efforts to target this network may be an effective strategy for treating glioma.


2021 ◽  
Author(s):  
I Pozios ◽  
E Günzler ◽  
N Hering ◽  
M Arndt ◽  
C Kamphues ◽  
...  

2010 ◽  
Vol 78 (2) ◽  
pp. 226-236 ◽  
Author(s):  
Indira Jutooru ◽  
Gayathri Chadalapaka ◽  
Maen Abdelrahim ◽  
Md Riyaz Basha ◽  
Ismael Samudio ◽  
...  

2008 ◽  
Vol 68 (11) ◽  
pp. 4360-4368 ◽  
Author(s):  
Hongkui Jin ◽  
Renhui Yang ◽  
Zhong Zheng ◽  
Mally Romero ◽  
Jed Ross ◽  
...  

Cancers ◽  
2020 ◽  
Vol 12 (6) ◽  
pp. 1412
Author(s):  
Chang Woo Han ◽  
Mi Suk Jeong ◽  
Sung Chul Ha ◽  
Se Bok Jang

Kirsten-RAS (KRAS) has been the target of drugs because it is the most mutated gene in human cancers. Because of the low affinity of drugs for KRAS mutations, it was difficult to target these tumor genes directly. We found a direct interaction between KRAS G12V and tumor suppressor novel H-REV107 peptide with high binding affinity. We report the first crystal structure of an oncogenic mutant, KRAS G12V-H-REV107. This peptide was shown to interact with KRAS G12V in the guanosine diphosphate (GDP)-bound inactive state and to form a stable complex, blocking the activation function of KRAS. We showed that the peptide acted as an inhibitor of mutant KRAS targets by [α-32P] guanosine triphosphate (GTP) binding assay. The H-REV107 peptide inhibited pancreatic cancer and colon cancer cell lines in cell proliferation assay. Specially, the H-REV107 peptide can suppress pancreatic tumor growth by reduction of tumor volume and weight in xenotransplantation mouse models. Overall, the results presented herein will facilitate development of novel drugs for inhibition of KRAS mutations in cancer patients.


2020 ◽  
Vol 401 ◽  
pp. 115118
Author(s):  
Ye Yao ◽  
Qing-yu Yao ◽  
Jun-sheng Xue ◽  
Xiu-yun Tian ◽  
Qi-ming An ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document